Investigating Out of Trend Results (OOT s) Dr. Pradeep Nagalkar Head Quality Control (Bio. & Chem.) Haffkine Bio-Pharma. Corp. Ltd.
|
|
- Louisa Montgomery
- 6 years ago
- Views:
Transcription
1 Dr. Pradeep Nagalkar Head Quality Control (Bio. & Chem.) Haffkine Bio-Pharma. Corp. Ltd., Mumbai
2 - We will be discussing - 1. What is OOT & OOS Examples of OOT & OOS Regulatory issues - 4. Method for detection of OOT - 5. Types of OOT - 6. Documentation / SOP Consideration Investigation - 8. Depth of investigation - 9. Conclusion
3 What is OOS and OOT OOS (Out Of Specification) is a comparison of one result verses a predetermined specification criteria while OOT (Out Of Trend) is a comparison of many historical data values verses time. OOS investigations focus on determining the truth about that one value while OOT investigation focus on understanding non-random changes.
4 What is OOS and OOT Example : The specification limit for assay is : % w/w of label claim 1. For a particular batch, the result obtained 94.2%w/w This result is out of specifications and is called OOS. An investigation is required. Root Cause Analysis (RCA) is required for OOS investigation. Once a root cause is identified, corrective and preventive measures need to be taken. 2. The result obtained 95.8 w/w. Although the results are well within the specifications, we should compare the result with the previous batches trend. If found the average value of the trend w/w then this batch result (95.8 w/w) is called Out Of Trend (OOT). A through understanding and control of the process is required.
5 OOS regulatory issues have been well understood and documented in the literature. However, OOT issues, for product stability, raw materials, in-process and finished product, data identification and investigation are less understood, but rapidly gaining regulatory interest. Though FDA s draft guidance indicates that much of the guidance presented for OOS can be used to examine OOT results, there is no clearly established legal or regulatory basis for requiring the consideration of data that is within specification but does not follow expected trend.
6 Methodology [3 sigma approach] A minimum of batches data shall be compiled for fixing the Trend range. Results that shall be obtained from the 25 batches tabulated, average value, minimum and maximum values are noted. Standard deviation will be calculated for these 25 batches. Excel spread sheet shall be used for Standard deviation calculation. Standard deviation will be multiplied by 3 to get the 3 sigma (3 )) value. Maximum limit will be arrived by adding the 3 1 value to the Average value of 25 batches. Minimum limit will be arrived by subtracting the 3 1 value from the Average value of 25 batches. Minimum value may come in negative also at times.
7 The maximum and minimum limits in above steps shall be taken as the Trend range for upper and lower limits. Any value that shall be out of this range will be considered as Out of Trend (OOT) value or Outlier value. Wherever specification has only Not more than, then only Maximum limit for trend can be considered. Minimum limit should be excluded. Wherever specification has only Not less than, then only Minimum limit for trend can be considered. Maximum limit should be excluded. Wherever specification has range then both the Maximum and Minimum limits for trend should be considered.
8 Methods of Identifying OOT Results 1. 3 sigma approach : Advantages: One advantage of this approach is that as long as the assumptions are met, the rate of false positives can be set when one calculates the limits. Disadvantage: The products with limited data, the appropriate limits may be difficult to determine. This can lead to wrongly centered, too narrow or too wide OOT limits. 2. Regression-Control-Chart Method: Advantage: Suitable for identification of the present OOT results in case where is no historical stability data. Disadvantage: The main disadvantage of this method is the necessity of having results for each time point due to the fact that the construction of the regression line was based on gradually adding the values in each subsequent time point.
9 Methods of Identifying OOT Results 3. The by-time-point Method: Advantages: The main advantage is that the absence of having a result in any time point did not affect the analysis of the previous or next point result. Disadvantage: A large history of data is preferred for proper use of this method. 4. Slope-Control-Chart Method: Advantage: Any small change in the value of the tested attribute from point to point is precisely recorded in the slope value of each time point. Disadvantage: If the test of the attribute were omitted in any time point for various reasons, the limits of that time point may not be appropriate. Dr.Pradeep Nagalkar / March 2015
10 There are mainly three types of OOT alerts: 1. An Analytical Alerts is observed when a single result is aberrant but with in specification limit ( i.e. outside normal analytical or sampling variation and normal change over time). 2. A Process Control Alerts occurs when a succession of data points shows an atypical pattern that was possibly caused by changes to the laboratory or manufacturing process. These data points might originate from the same stability study or from multiple studies assayed within a reasonably close time. Despite the deviating trends, no pending potential OOS situation occurs.
11 There are mainly three types of OOT alerts : 3. A Compliance Alert defines a case in which an OOT result suggests the potential or likelihood for OOS results to occur before the expiration date within the same stability study (or for other studies) on the same product.
12 SOP for OOT : Considerations An investigation's depth may depend on the nature of the data, the product history and characteristics being measured, the potential risk to product quality, and the potentially related safety or efficacy implications. A review of the OOT alert procedures' performance might coincide with the annual product review. When preparing an SOP for handling OOT test results, it is prudent to consider risks to product quality when determining the company's assessment of OOT test results. The depth of an investigation and the corrective measures taken may depend on the potential or implied risk to product quality.
13 SOP for OOT : Considerations How to set alert limits :SOPs may identify scientifically sound approaches to determine procedures with associated limits for the identification of each type of OOT alert for stability test attributes such as assay and degradation products. Once an approach is identified, some potential topics to be included in the SOP are data requirements, personnel responsible for setting the limits, and methods used to detect each type of OOT alert.
14 SOP for OOT : Considerations How to set alert limits: For new products, available stability data will be limited. Established products often will have sufficient historical data. The method for detecting OOT results may vary depending on the type of OOT alert. Ideally, a method for each OOT should be specified. How to use limits : The SOP may contain a section about how OOT alert limits are applied and which personnel will be responsible for comparing new stability results with the OOT alert criteria and timeliness of the review.
15 SOP for OOT : Considerations Investigation : Investigation requirements could include personnel responsibilities with defined timelines, documentation requirements, and proper internal notification requirements. The investigation's depth required for each OOT alert will depend on potential risks to product quality. The SOP should not be overly prescriptive because the steps taken to investigate OOT results will depend on the nature of the initial finding and the investigation findings.
16 SOP for OOT : Considerations Investigation : Nonetheless, SOPs should provide basic criteria for conducting the investigations. Moreover, the steps taken to investigate OOT results should be scientifically defensible, and the rationale for the investigation's depth should be documented. Although an OOT result usually will be investigated as soon as possible after it is identified, it also can be addressed more broadly during the annual product review. The notification requirements and the department responsible for performing the annual product reviews also could be included.
17 SOP for OOT : Considerations Depth of Investigation : If an analytical alert is observed, a laboratory investigation may be performed. If the laboratory investigation is inconclusive, then the supervisor may take no further action at that time and monitor subsequent time points closely. A review of results for related or correlated test attributes also can facilitate the investigation. Depending on the product, history, and nature of the analytical alert data, the company may decide to investigate whether a manufacturing error occurred in cases in which a laboratory error is not conclusive.
18 SOP for OOT : Considerations Investigation : More data (i.e., the next stability test point) may be needed to indicate whether the result is part of a longterm trend (process control alert) or just an isolated result. If subsequent results within the study and across other studies are not out of trend, then the initial analytical alert result may be an isolated incident that requires no further investigation.
19 SOP for OOT : Considerations Investigation : A process control alert may indicate unexpected changes in product or assay performance. A stability study with an unusual trend may reveal that a characteristic's stability profile changed, whereas multiple analytical alerts may suggest that the measurement process is no longer in control.
20 SOP for OOT : Considerations Investigation : When a process control alert is evident, the investigation will often begin with an assessment of the effect of potential changes to the laboratory process (e.g., changes in instrument, column, integration technique, or standard). It also may extend to the manufacturing process (e.g., looking for changes in materials, personnel, equipment, and procedures).
21 SOP for OOT : Considerations Investigation : A compliance alert identifies a situation in which a particular study (or several related studies) may not meet specification limits during the expiration period, one may need to conduct a thorough investigation. In general, this investigation begins with the laboratory process and expands to the manufacturing process if no conclusive laboratory root cause is identified. The manufacturing investigation might include other batches (from the same or related products) that may be associated with this predicted failure to identify whether the discrepancy is isolated or systematic.
22 SOP for OOT : Considerations Investigation : The investigation also could assess whether more analytical testing, an investigation into the manufacturing process, a product recall, or shorter dating is required. An investigation of a compliance alert aims for the early detection of potentially failing product and the identification of possible causes. If a root cause is determined, then appropriate action should be taken such as the identification of potential preventative actions.
23 SOP for OOT : Considerations Periodic review of limits : SOPs may specify a periodic review process for OOT alert limits. The frequency of the review and the personnel responsible for completing it may be addressed in the SOPs. This assessment can involve identifying a previous result that was once within trend but is now an OOT result. Or, it may find that a previous OOT result is now within trend. It is natural that earlier conclusions be revised in light of new information because developing OOT alert criteria is an active and continuing process.
24 Conclusion : Identifying OOT results is a growing interest for FDA and vaccine Industry point of view. Despite this, very little has been discussed in the scientific literature or in regulatory guidance on this topic. The vaccine industry still lacks having a proper guideline for the identification of OOT results among results. As a result, industry is not harmonized in the way they conduct OOT analysis. The method to determine an OOT should not be too complex. However, some-thing too simplistic may not be sensitive enough to identify a true OOT or may give a high rate of false signals.
25 Conclusion : Challenges: What statistical approach should be used for OOT assessment, What minimum data to be used, What data to be used for updating the limits, How is an OOT result is confirmed, What action to be taken if an OOT result is confirmed, How are OOT investigation incorporated in APR
26 Thank you
1 of 9 2/7/ :53 PM. Identification of Out-of-Trend Stability Results, Part II PhRMA CMC Statistics, Stability Expert Teams
1 of 9 2/7/2006 10:53 PM Identification of Out-of-Trend Stability Results, Part II PhRMA CMC Statistics, Stability Expert Teams 2 of 9 2/7/2006 10:53 PM Oct 2, 2005 By: PhRMA CMC Statistics, Stability
More informationINVESTIGATE OOT AND OOS IN STABILITY STUDIES
INVESTIGATE OOT AND OOS IN STABILITY STUDIES Kim Huynh-Ba Executive Director Pharmalytik LLC www.pharmalytik.com BIOGRAPHY Kim Huynh-Ba has over 25 years of experience in analytical development, project
More informationGuidance for Industry
Guidance for Industry Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationLaboratory OOS Investigations The Missing Link
Laboratory OOS Investigations The Missing Link India Pharmaceutical Alliance Carmelo Rosa, Psy.D Director Division of Drug Quality I November 6-17, 2017 Indian Pharmaceutical Alliance DISCLAIMER: The views
More informationEstablishing Chemistry QC Ranges
Chemistry Guideline for Establishing New Control Lot Means and Quality Control (QC) Ranges Through Parallel Testing and Historic Coefficient of Variation (%CV h ) Authored by Kurt Michael and Paul Richardson
More informationHandling OOS, OOT and Unexpected Results. Karen Ginsbury PCI Pharmaceutical Consulting Israel Ltd for IFF, October 2017
Handling OOS, OOT and Unexpected Results Karen Ginsbury PCI Pharmaceutical Consulting Israel Ltd for IFF, October 2017 What is an OOS What is an OOT What is an Unusual, Questionable, Atypical Result Objective:
More informationGood Manufacturing Practice ( GMP ) Compliance: GMPs EXPLAINED
Good Manufacturing Practice ( GMP ) Compliance: GMPs EXPLAINED Presented by Raymond A. Bonner Nathan C. Sheers SIDLEY AUSTIN BROWN & WOOD, LLP Washington, D.C. (202) 736-8000 To The Fourth Annual Pharmaceutical
More informationOut of Specification & Out of Trend Investigations. October 2017
Out of Specification & Out of Trend Investigations October 2017 How to use the Investigation Flowchart Navigation: Clicking on those Process Step boxes with a heavy border in a process flow will take you
More informationOvercome the Top Challenges of Handling OOS Results by Knowing FDA Observations
Overcome the Top Challenges of Handling OOS Results by Knowing FDA Observations Jerry Lanese Ph.D. The Lanese Group, Inc. 2015 The Lanese Group, Inc. 1 Who decided you should come to this conference? On
More informationCERTIFIED MAIL RETURN RECEIPT REQUESTED
Department of Health and Human Services Public Health Service Food and Drug Administration Warning Letter WL: 320-14-11 CERTIFIED MAIL RETURN RECEIPT REQUESTED June 16, 2014 Jeremy B. Desai, PhD President
More informationProcess Validation Guidelines. Report highlights 23 rd February 2018
Process Validation Guidelines Report highlights 23 rd February 2018 Process validation is an important element of pharmaceutical quality system An effective system provides assurance of the continued capability
More informationAnnual product quality review: Guidance for industry by regulatory perspective
International Journal of Medicine Research ISSN: 2455-7404; Impact Factor: RJIF 5.42 www.medicinesjournal.com Volume 2; Issue 4; July 2017; Page No. 01-10 Annual product quality review: Guidance for industry
More informationThe FDA Just Arrived... Are You Ready? Presented By Sandra Lueken Sr. Director, Quality AstraZeneca Biologics
The FDA Just Arrived... Are You Ready? Presented By Sandra Lueken Sr. Director, Quality AstraZeneca Biologics Objectives Review Quality Systems Audit Approach and cgmp fundamentals Logistical Audit Preparation
More informationOOS: Back to Basics. Compliant, Effective, Efficient PATH
OOS: Back to Basics Even with the number of trainings, seminars, online webinars and consultant guided investigations, companies are still seeing FDA 483 observations around how they are handling and investigating
More informationICH Q8/Q8(R)
Pharmaceutical Quality for the 21 st Century Temple University May 06, 2008 Joseph Famulare, Deputy Director FDA CDER Office of Compliance CDER Office of Compliance and the Critical Path Initiative Since
More informationGMP Challenges to Global Pharma Companies
GMP Challenges to Global Pharma Companies Muralidhara B. Gavini, Ph.D. Senior Assistant Country Director India Mumbai Office, Office of International Programs Office of the Commissioner Food & Drug Administration
More informationManual 029 Deviation Management
1 Purpose The purpose of this guideline is to outline the requirements for the reporting, investigation and handling of individual deviations, and to outline a systematic approach for the trending of deviations,
More informationTop Annual 483 Observations: The Cycle of Quality June 2017 Presented by: Susan Schniepp
Top Annual 483 Observations: The Cycle of Quality June 2017 Presented by: Susan Schniepp 2016 Regulatory Compliance Associates Inc. Top Observation for 5 years Year Drugs #1 citation Device #1 citation
More informationSolving Statistical Mysteries What Does the FDA Want?
3 7 25Temperature(degC) 40 3.4 6.6 2.6 3.6 75 Humidity % 1.6 5.3 50 No Base Present Yes Solving Statistical Mysteries What Does the FDA Want? Ronald D. Snee, PhD IVT Statistics in Validation Conference
More informationA COMPARATIVE FRAMEWORK BETWEEN NEW PRODUCT & LEGACY PRODUCT PROCESS VALIDATION
A COMPARATIVE FRAMEWORK BETWEEN NEW PRODUCT & LEGACY PRODUCT PROCESS VALIDATION By Mark Mitchell, Principal Consultant, Process and Engineering, Pharmatech Associates, Inc. PHARMATECH WHITE PAPER.DOCX
More informationMeasurement Uncertainty Guide. ISO Accreditation Program
Measurement Uncertainty Guide ISO 15189 Accreditation Program Background Why This is Necessary The ISO 15189:2012 standard contains enhanced expectations regarding measurement uncertainty (MU) in clause
More informationComplaints Investigations Root Cause Analysis
Complaints Investigations Root Cause Analysis Dr. Ademola Daramola International Relations Specialist Drugs US FDA India Office New Delhi February 22nd 2018 Information presented in this presentation does
More informationQUALITY AGREEMENT. The following Agreement has been concluded between
QUALITY AGREEMENT The following Agreement has been concluded between LLC LABORATORIES The contract laboratory and service provider 1625 Trinity Dr., Unit 11 Mississauga, Ontario Canada L5T 1W9 Hereinafter
More informationAuditing Your Laboratory for Compliance with the FDA Dietary Supplement GMP s
Tech Tip 0020 With the advent of the cgmp s, the majority of companies are increasing the frequency of their outsourced analytical testing. But the GMPs are just that, Good Manufacturing Practices, and
More informationPrincipal approach to CPV :
Principal approach to CPV : Integration with Quality Systems & Operating Mechanisms J. Gampfer, Baxalta, Vienna Austria Baxalta Principal Approach to CPV J. Gampfer Page 1 Baxalta Principal Approach to
More informationMEASURE FOR MEASURE: QUALITY METRICS
MEASURE FOR MEASURE: QUALITY METRICS PDA Midwest Chapter Dinner Meeting, Northbrook, IL-9 November 2017 Felicia Ford-Rice, Director, Strategic Compliance 2017 PAREXEL INTERNATIONAL CORP. AGENDA Robust
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 5 Inspections, Compliance, Enforcement, and Criminal Investigations Hill Dermaceuticals, Inc. Department of Health and Human Services Public Health Service Food and Drug Administration Food and
More informationPage 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Compliance Actions and Activities Warning Letters 2014 Inspections, Compliance, Enforcement, and Criminal Investigations
More informationWARNING LETTER CMS #
U.S. Food and Drug Administration Division of Pharmaceutical Quality Operations I 10 Waterview Blvd 3rd FL, Parsippany NJ 07054 Telephone: (973) 331-4900 Fax: (973) 331-4969 www.fda.gov Via UPS Next Day
More informationQUALITY ASSESSMENT METHODS FOR NEW PRODUCT LAUNCHES: PROCESS VALIDATION LIFECYCLE
QUALITY ASSESSMENT METHODS FOR NEW PRODUCT LAUNCHES: PROCESS VALIDATION LIFECYCLE NAHEED SAYEED-DESTA APOTEX INC. CANADIAN SOCIETY FOR QUALITY 9 TH QUALITY CONGRESS SEPTEMBER 7-8, 2017 OUTLINE Introduction
More informationEVALUATION FOR STABILITY DATA
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION FOR STABILITY DATA Q1E Recommended for
More informationOverview of Inspection Issues with Legacy Products
Overview of Inspection Issues with Legacy Products Presented by Simone E. Pitts Consumer Safety Officer, USFDA Team Biologics simone.pitts@fda.hhs.gov Objective To provide some examples of recent inspectional
More informationLessons from Pharmaceutical Laboratory related FDA Warning Letters
Lessons from Pharmaceutical Laboratory related FDA Warning Letters The Agilent Critical Compliance Seminar 2016 Ludwig Huber Ludwig_huber@labcompliance.com Overview FDA Inspections and reports GMP compliance
More informationVital Laboratories Pvt Ltd Plant II 10/10/17
Vital Laboratories Pvt Ltd Plant II 10/10/17 10903 New Hampshire Avenue Silver Spring, MD 20993 Via UPS Warning Letter 320-18-01 October 10, 2017 Mr. Rajiv Bajaj Director Vital Laboratories Private Limited
More informationWhile the recognition
Designing the Perfect Change Control System Change control systems today are expected to be designed in a way that provides a system to not only document and approve changes, but also to anticipate change
More informationManual 058 Out of Specification Results Investigation
1 Purpose The purpose of this Guideline is to provide guidance for the investigation and response to Out of Specification (OOS) laboratory test results. 2 Scope and Applicability This Guideline applies
More informationCOMMERCIAL PRODUCT STABILITY
COMMERCIAL PRODUCT STABILITY Being Responsible for your Tweener, Senior Citizen and Hospice Stage Products Melissa Lambert Global Head Stability in Quality & Compliance Management, R&D Director Quality
More informationDocumenta tion and Records
Documenta tion and Records Page 1 of 30 Training Outcome of the Module: After completing this module, you will be able to: Recognize the importance of procedures Recognize the importance of record keeping
More informationStandard Operating Procedure Title: Initial Investigation of Out of Specification (OOS) Results in Microbiological Laboratory
Department Micro Laboratory Document no MICLAB 145 Title 1.0 DOCUMENT OWNER Laboratory/Quality Manager 2.0 PURPOSE To establish a procedure for the investigation of initial out-of-specification (OOS) or
More informationPROCESS VALIDATION ANSM 2015 FDA 2011
PROCESS VALIDATION ANSM 2015 FDA 2011 PBE-Expert Inc CANADA Training Company Agreement CPMT #0059104 Qualified Consultant At the measure 2 of the Levier Program PBE, Training Company Agreement CPMT #0059104
More informationUnimark Remedies Limited 8/12/16
SHARE TWEET PRINT Unimark Remedies Limited 8/12/16 Department of Health and Human Services Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 Via UPS
More informationFDA Process Validation
Page 1 of 5 Published on Controlled Environments Magazine (http://www.cemag.us) Home > FDA Process Validation FDA Process Validation Wai Wong Working with the New 2011 Guidelines. In January 2011, the
More informationData Integrity Prioritization and Gap Analysis to Prove Data Integrity
Data Integrity Prioritization and Gap Analysis to Prove Data Integrity Oct 9 th 2018 Speakers Alex Brindle Principal Consultant with DPS. Alex holds a B.Sc. in Chemistry, a M.Sc. in Analytical Science
More informationCDER /OPQ Office of Surveillance Quality Metrics in Surveillance
CDER /OPQ Office of Surveillance Quality Metrics in Surveillance Russell Wesdyk Acting Director Office of Surveillance Office of Surveillance Goals Builds from the shared vision A maximally efficient,
More informationOUT OF SPECIFICATION. SASIDA YOOSOOK 4 April 2014
OUT OF SPECIFICATION SASIDA YOOSOOK 4 April 2014 ISO 17025:2005 4.9 Control of nonconforming testing and/or calibration work 4.9.1 The laboratory shall have a policy and procedures that shall be implemented
More informationSQL*LIMS Stability Analytics Software
SQL*LIMS Stability Analytics SQL*LIMS Stability Analytics Software Real-Time Analysis At-Your-Fingertips A purpose-built analytics solution that puts meaningful information at the fingertips of your Stability
More information2014 IPA / EDQM 4 TH TECHNICAL CONFERENCE QUALITY OF PHARMACEUTICAL INGREDIENTS. September 15,
2014 IPA / EDQM 4 TH TECHNICAL CONFERENCE QUALITY OF PHARMACEUTICAL INGREDIENTS - APPLYING LEARNINGS TO PRACTICE September 15, 2014 1 CONTENTS INTRODUCTION PRESENT STATE OF PHARMACEUTICAL INDUSTRY MANUFCTURING
More informationOverview of Regulatory Requirements for API and Formulations
Overview of Regulatory Requirements for API and Formulations Sangeeta Sardesai 4-Dec-2010 Definition - Regulatory Requirement The restrictions, licenses, and laws applicable to a product or business, imposed
More informationLifecycle Product Quality Risk Management
Lifecycle Product Quality Risk Management Richard L. Friedman, M.S. Associate Director Office of Manufacturing and Product Quality Office of Compliance IFPAC Annual Meeting (Arlington, VA) January, 21-24,
More informationInvestigating OOS for Finished Product on the Stability Program. Presented by: Nicole Chang, QA Manager, Apotex Pty Ltd
Investigating OOS for Finished Product on the Stability Program Presented by: Nicole Chang, QA Manager, Apotex Pty Ltd Overview 1. Requirements of the commercial stability program 2. Out of Specification
More informationICH Q10/WHO TRS A Regulatory Perspective
Presentation by: Dr. A. Ramkishan Asst. Drugs Controller (India) Govt. of India ICH Q10/WHO TRS A Regulatory Perspective Contents of Presentation Introduction History of WHO GMP TRS guidelines A Unique
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT (WHOPIR) Active Pharmaceutical Ingredient (API) Manufacturer
Prequalification Team WHO PUBLIC INSPECTION REPORT (WHOPIR) Active Pharmaceutical Ingredient (API) Manufacturer PART 1: GENERAL INFORMATION Name of Manufacturer Calyx Chemicals & Pharmaceuticals Ltd Unit:
More informationAddressing the Paradigm Shift in Regulatory Inspections
An Executive Summary Addressing the Paradigm Shift in Regulatory Inspections Understanding the paradigm shift in a regulatory audit and what it means from an electronic system perspective. Humera Khaja
More informationGuidance for Industry Process Validation: General Principles and Practices. F. Hoffman-La Roche, Ltd.
Guidance for Industry Process Validation: General Principles and Practices D M k T k Dr. Mark Tucker, F. Hoffman-La Roche, Ltd. Disclosures I am currently a Senior Technical Advisor at F. Hoffman -La Roche.
More informationFDA Quality Metrics Guidance
FDA Quality Metrics Guidance Marlène García Swider, Ph.D., CQM, CSSBB Institute of Validation Technology Quality Metrics Conference February 22 24, 2016 Coronado Island, San Diego, CA Personal Claim This
More informationBest practices in Quality Metrics. Vivek Arora Partner, McKinsey & Company IPA CONFERENCE FEBRUARY 2019
Best practices in Quality Metrics Vivek Arora Partner, McKinsey & Company IPA CONFERENCE FEBRUARY 209 Management reviews & quality metrics have existed for a while Management review should provide assurance
More informationCA Cannabis Regulations Review of Manufacturing and Track and Trace Requirements
CA Cannabis Regulations Review of Manufacturing and Track and Trace Requirements Executive Summary InstantGMP, Inc. provides a complete solution for manufacturing products that comply with Good Manufacturing
More informationData Integrity Issues in Today s Complex and Global Manufacturing Supply Chain: Regulatory Perspective
Data Integrity Issues in Today s Complex and Global Manufacturing Supply Chain: Regulatory Perspective Derek S. Smith, Ph.D. Office of Pharmaceutical Quality Office of Process and Facilities AAM FallTech
More informationStatistical Evaluation Of Stability Data
Reprinted from FDA s website by #219 GUIDANCE FOR INDUSTRY Statistical Evaluation Of Stability Data VICH GL51 DRAFT GUIDANCE This guidance document is being distributed for comment purposes only Submit
More informationGMP for ATMP. Advanced Therapy Medicinal Products Key2Compliance AB
GMP for ATMP Advanced Therapy Medicinal Products 2018 Key2Compliance AB 1 Content Background and regualtory requirements GMP Walkthrough Quality Risk Management 2018 Key2Compliance AB 2 Background and
More informationGuidance for Industry Process Validation: General Principles and Practices; A Contract Manufacturing Organization's Approach
May -3, 202 Javits Center New York, NY Guidance for Industry Process Validation: General Principles and Practices; A Contract Manufacturing Organization's Approach Sandra Lueken Director of Quality Baxter
More informationProduct quality reviews
Product quality reviews Document valid from: 07.11.2017 Document number: I-SMI.TI.14 Version no. 05 Classification: Public Replaced document: I-SMI.TI.14_04 dated: 14.08.2014 Root QMI documents: - Referenced
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Seite 1 von 10 Inspections, Compliance, Enforcement, and Criminal Investigations Laboratoire Atlas Inc. 6/25/09 hhsbluebird Department of Health and Human Services Public Health Service Food and Drug Administration
More informationNotes for Production and Operations Management- I
Notes for Production and Operations Management- I Factors affecting Process Design Decisions Nature of product/service demand Degree of vertical integration Production Flexibility Degree of automation
More informationLABORATORY COMPLIANCE
1 LABORATORY COMPLIANCE Jeanne Moldenhauer Vectech Pharmaceutical Consultants, Inc. Farmington Hills, MI INTRODUCTION Implementation of the Systems-Based Inspection Guideline for drug manufacturers in
More informationProduct Quality Review: Overview and Feedback from Inspection
Product Quality Review: Overview and Feedback from Inspection GMP/Market Compliance Information Day October 23 rd 2008 Lorraine Nolan Acting Inspection Manager IMB Slide 1 Scope of Presentation Overview
More informationSCIENCE AND RISK BASED APPROACH TO THE PROCESS VALIDATION LINK FROM QUALITY BY DESIGN TO PROCESS VALIDATION.
IJPSR (2016), Vol. 7, Issue 3 (Review Article) Received on 09 September, 2015; received in revised form, 15 December, 2015; accepted, 05 February, 2016; published 01 March, 2016 SCIENCE AND RISK BASED
More informationPharmaceutical Good Manufacturing Practice. Contents are subject to change. For the latest updates visit
Pharmaceutical Good Manufacturing Practice Page 1 of 6 Why Attend A robust quality system that meets the requirements of pharmaceutical regulators is an essential element of every good pharmaceutical manufacturing
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 6 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Lloyd Inc. of Iowa
More informationJournal of Chemical and Pharmaceutical Research
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 0975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 2011, 3(6):88-98 Conduct of Inspections for Pharmaceutical Manufactures
More informationPractical Applications of Statistical Methods Under 2011 FDA Process Validation Guidance
Practical Applications of Statistical Methods Under 2011 FDA Process Validation Guidance Abe Germansderfer Associate Director, Quality Control Gilead Sciences 2011 Process Validation Guidance In January
More informationPrequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Tablets
Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: information about the inspection Name of manufacturer Physical address production departments
More informationVICH Topic GL2 (Validation: Methodology) GUIDELINE ON VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit CVMP/VICH/591/98-FINAL London, 10 December 1998 VICH Topic GL2 (Validation: Methodology) Step 7 Consensus
More informationThe Use of Pharmaceutical Stability Tools in Medical Device Stability Programs
Global SYNTHES Institute of Validation Technology Forum on Stability Programs The Use of Pharmaceutical Stability Tools in Medical Device Stability Programs Laure L. Larkin MSc. CPP. Synthes USA 1 The
More informationChange Control Overview
Change Control Overview Kelly Thomas Atlantic Technical and Validation Services Copyright 2014 by Atlantic Technical and Validation Services, LLC. 1 Session Outline Discuss Regulations Governing Change
More informationJGK TRAINING PROGRAMME MODULE 2: METHOD VALIDATION AND MEASUREMENT OF UNCERTAINTY IN VETERINARY LABORATORIES PRACTICAL COURSE
Registered as JKG Lab AfriQA (Pty) Ltd Reg. No. 2012/154570/07 P.O Box 1581 Potchefstroom 2520 3 Sylvia Street `` Potchefstroom 2531 Tel: +27 18 294 4528 Fax: +27 86 650 1716 Cell: +27 82 562 1858 Email
More informationVALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *)
VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *) Guideline Title Validation of Analytical Procedures: Methodology Legislative basis Directive 75/318/EEC as amended Date of first adoption December 1996
More informationShelf life planning on SAP Integrated Business Planning Deloitte and SAP co innovation
Shelf life planning on SAP Integrated Business Planning Deloitte and SAP co innovation Deloitte s approach to tackle shelf life planning on SAP IBP Shelf life planning solution addresses the challenge
More informationSQF 2000 Guidance. Guidance for Food Sector Category 4 Fresh Produce Pack House Operations. 1st Edition
SQF 2000 for Food Sector Category 4 Fresh Produce Pack House Operations 1st Edition SEPTEMBER 2010 Safe Quality Food Institute 2345 Crystal Drive, Suite 800 Arlington, VA 22202 USA 202-220-0635 www.sqfi.com
More informationSpeaker: Neville Taylor
Paper: The importance of Stability Testing in Proficiency Testing Author: Vijay Padayachee Vijay Consulting cc PO Box 2707, Johannesburg, 2000, South Africa E-mail: vpad@telkomsa.net Phone: +27 825795242
More informationQUALITY SYSTEMS INSPECTIONS TECHNIQUE
QUALITY SYSTEMS INSPECTIONS TECHNIQUE Notice: This draft document represents the Agency' current thinking on the subject of Quality System Inspections. It is provided to the public in order to stimulate
More informationStrategic Implantation of PAT : FDA Perspective
Strategic Implantation of PAT : FDA Perspective Moheb M. Nasr, Ph.D. CDER, FDA MOHEB.NASR@FDA.HHS.GOV IFPAC 2008 Strategic Implantation of PAT Baltimore, MD January 27, 2008 Outline The Desired State -
More informationVICH Topic GL49. at step 4 GUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS USED IN RESIDUE DEPLETION STUDIES
European Medicines Agency Veterinary Medicines and Inspections London, 14 December 2009 Doc. Ref. EMEA/CVMP/VICH/463202/2009-CONSULTATION VICH Topic GL49 at step 4 GUIDELINES FOR THE VALIDATION OF ANALYTICAL
More informationUPPLIER ANUAL. Issued: 01 Aug 13
UPPLIER ANUAL Issued: 01 Aug 13 Table of Contents Our Company 3 Our Vision 3 Scope and Purpose 4 Responsibilities 4 General Expectations and Requirements 5 Supplier Quality Management System 6 Supplier
More informationProcess Drift: When Do We Detect it? Richard L. Friedman Director, DMPQ CDER/Office of Compliance PQRI Process Drift Workshop December 1, 2010
Process Drift: When Do We Detect it? Richard L. Friedman Director, DMPQ CDER/Office of Compliance PQRI Process Drift Workshop December 1, 2010 Overview Goal of Manufacturing Central Question: Why is process
More informationSampling Definitiion Sampling is the process of systematically selecting that which will be examined during the course of a study.
Sampling Definitiion Sampling is the process of systematically selecting that which will be examined during the course of a study. Types of Sampling Approaches There are a wide range of sampling approaches.
More informationISPE-FDA 3 rd Annual CGMP Conference 2 4 June 2014 Baltimore, MD. Detecting GMP Data Integrity Issues
Detecting GMP Data Integrity Issues Elaine Eborall Senior Director, GMP Compliance, Americas and Asia Pacific Compliance and External Collaboration ISPE-FDA cgmp Conference Baltimore, Maryland 2-4 June
More informationChemical Aspects of Stability Evaluation
Chemical Aspects of Stability Evaluation 8 steps to generating stability data which speaks for itself Alan Doughty Chief Chemist Pty Ltd Aim of a stability trial Obtain data which allows a definitive conclusion
More informationEffective Management and Operations of GXP Laboratories
Effective Management and Operations of GXP Laboratories Course Objective: Upon completion of this course, attendees involved in establishing and assuring that Good Laboratory / Good Manufacturing Practice
More informationEVOLVING TRENDS IN THE USE OF STATISTICS FOR PROCESS VALIDATION IVT 3 RD ANNUAL STATISTICS IN VALIDATION JUNE 20-22, 2017
EVOLVING TRENDS IN THE USE OF STATISTICS FOR PROCESS VALIDATION IVT 3 RD ANNUAL STATISTICS IN VALIDATION JUNE 20-22, 2017 KATHERINE GIACOLETTI PARTNER, SYNOLOSTATS LLC OUTLINE Background How we got to
More informationWHO post-market surveillance of in vitro diagnostics
WHO post-market surveillance of in vitro diagnostics Geneva, 27 November 2015 Anita Sands Prequalification Team World Health Organization About post-market surveillance of IVDs > Some quality, safety and
More informationPrice Electronics,LLC Quality Assurance Manual
Price Electronics,LLC QUALITY POLICY INTRODUCTION The purpose of this manual is to document the company s quality system, to instruct and guide employees whose actions affect product quality and to inform
More informationProcess Monitoring Applying QbD Principles in a Biopharmaceutical Environment
WCBP 205- CASS Conference Washington DC, July-20 to 2, 205 Process Monitoring Applying QbD Principles in a Biopharmaceutical Environment Michael Kraus PhD MBB Process Science & Technical Operations Baxalta
More informationStatistics Quality: Control - Statistical Process Control and Using Control Charts
Statistics Quality: Control - Statistical Process Control and Using Control Charts Processes Processing an application for admission to a university and deciding whether or not to admit the student. Reviewing
More informationCEC SDG Glossary of Terms Notes
CEC SDG Glossary of Terms Notes - Terms are listed alphabetically - Acronyms are either identified by underlined words (e.g. Co-ordinating European Council), or refer to a separate full-text entry - Each
More informationManagement of Out of Specification (OOS) for Finished Product
Available online at www.ijpcr.com International Journal of Pharmaceutical and Clinical Research 2017; 9(3): 221-232 doi: 10.25258/ijpcr.v9i3.8323 ISSN- 0975 1556 Research Article Management of Out of Specification
More informationVICH GL51: Quality: statistical evaluation of stability data
1 2 3 12 December 2011 EMA/CVMP/VICH/858875/2011 Committee for Medicinal Products for Veterinary Use (CVMP) 4 5 VICH GL51: Quality: statistical evaluation of stability data Draft Draft agreed by VICH Steering
More informationYes, there is going to be some math (but not much) STATISTICAL APPROACH TO MEDICAL DEVICE VERIFICATION AND VALIDATION
Yes, there is going to be some math (but not much) STATISTICAL APPROACH TO MEDICAL DEVICE VERIFICATION AND VALIDATION Medical Device Verification and Validation In the medical device world, verification
More informationWHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products
WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products 1. Introduction 1.1 Objectives of these guidelines 1.2 Scope of these guidelines 1.3 General principles
More information